PMV Pharmaceuticals, Inc. - 8-K Filing

PMV Pharmaceuticals priced $47M underwritten offering on Aug. 31, 2026 for rezatapopt development (Items: 1.01 Entry into a Material Definitive Agreement, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $PMVP

Read the full article at SEC EDGAR

More Regulatory news